Catalog No.: PC-43290Not For Human Use, Lab Use Only.
R-268712 is a potent, selective, orally active inhibitor of TGF-β type I receptor ALK5 with IC50 of 2.5 nM, >5,000-fold more selectivity than p38 MAPK.
R-268712 is a potent, selective, orally active inhibitor of TGF-β type I receptor ALK5 with IC50 of 2.5 nM, >5,000-fold more selectivity than p38 MAPK.
R-268712 inhibits the development of renal fibrosis in a dose-dependent manner in a unilateral ureteral obstruction (UUO) model at doses of 1, 3 and 10mg/kg.
R-268712 also reduces proteinuria and glomerulosclerosis significantly with improvement of renal function in glomerulonephritis models.
